OC Skin Institute's Dr. Tony Nakhla, an expert in the medical dermatology field, reviews facts concerning Pilomatrical Carcinoma and refers to further details obtained from a case study. Dr. Nakhla now runs his own practice in Orange County California, where he provides treatments for all dermatological needs, including acne, skin cancer detection, mole & wart removal, and skin allergy testing.
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Pilomatrical Carcinoma: A Case Report by Dr. Tony Nakhla of OC Skin Institute
1. PilomatricaICarcinoma:
CaseReportandReviewof
theLiterature
Tony Nakhla, DO; Michael Kassardjian, DO
Pilomatricalcarcinomaisa raremalignanttumorthatoriginatesfromhairmatrixcells.Pilomatrical
carcinomamay arisede novo as a solitarylesion,or throughtransformationfrom its benign
counterpart,pilomatrixoma.Differentiationbetweenpilomatrixomaand pilomatricalcarcinoma
requiresclosehistologicexaminationand often is difficult.Althoughuncommon,pilomatrical
carcinomahasthe potentialto metastasize;therefore,promptdiagnosisandappropriatemanage-
mentisessential.
ilomatrical carcinoma is the malignant
counterpart of pilomatrixoma, a benign
cutaneous tumor originating from the hair
ma[rix. It is a rare, aggressivetumor with a
high probability of recurrence after simple
excision, and the potential to metastasrze.
We report a case of a 56-year-old white man
diagnosed with pilomatrical carcinoma. The patient
presented with a 2-month history of ar1 enlarging
asymptomatic growth on the cheek. Physical exami-
nation revealed a 2-cm, well-demarcated, nontender,
moveable, hard subcutaneous nodule on the right
mandible (Figure l). No skin changes or lymphad-
enopathy was noted. The clinical diagnosis strongly
favored a calcified epidermoid cyst or other benign
adnexal tumor. An excisional biopsy was performed at
the request of the patient.
Sections were evaluated histologically and revealed
a multifragmented biopsy of dermal and subcutaneous
tissue containing basaloid proliferation with collections
of ghost cells, typical of pilomatrixoma (Figure 2).
Dr. I'laLthlais from OC Shin Institute, Santa Ana, California.
Dr. Kassardlianisan intern,PacificHospital,LongBeach,California.
The authors report no conflict tf interest in relation to
thisarticle.
Correspondence:Michael Kassardjian,DO, PO Box 2152,
PalosVerdesPen,CA 90275(miheygh@gmail.com).
3I4 CosmeticDermatology@. JULY2010. vol. 23No.7
In som e areas,the lesional cells are relatively bland and
noninfiltrative appearirg.
However, this case also shorvs areaswith larger more
squamoid appearing cells urth aLyprcalfeatures, includ-
irg Iargenuclei with prominent nucleoli aswell as areasof
infiltrative appearing cells, features highly concerning for
malignancy (Figure 3). In the infiltrative appearrngarea,
there is dense stromal sclerosis associated u-ith highly
atyprcal squamoid and spindle cells, with ser-eralmitotic
figures found within these cells (Figure +) In many
areas of the biopsy, there is granulomatolls inflamma-
tion, hemorrhage , and granulation tissue consistent
with a reaction to ruptured material from the tumor
(Figure 5) While the latter findings often are seen in
ruptured pilomatrixoma, the infiltratn-e areas with
atyprcal spindle cells would not be erpected in a
benign pilomatrixoma, and the findings are most con-
sistent with a diagnosis of malignant pliomarrixoma
(pilom afitcal carcinoma) .
Multiple laboratory tests using immunohrstochemi-
cal stains, including p63, cytokeratrn i/6, synap-
tophysin, p53, and Ki-67 also -ere rer-iewed. The
tumor cells were strongly and diffusely- positive for
p63, highlighting the nuclei of the infiltrative and
spindle cells, which is positirre in mos[ primary cuta-
neous malignancies including adnexal carcinomas. In
addition, results of cytokeratin 5/6 staining aiso were
moderately positive within lesional cells, including the
www.cosderm.com
2. infiltrative-appearing spindle cells, which confirmed
that these were epithelial, and not mesenchymal,
ceiis R.esults of synaptophysin staining were nega-
[l-e and not consistent with a neuroendocrine tumor
such as ierkel cell carcinoma. Staining for p53 was
r.,'eakirb'-ri difiusely positive throughout the tumor cell
nuclei. rnc^'-rd.rnEthe infiltrative areas, a finding that
also far-ored :rahgnancy. In addition, Ki-67 positivity
was high u ithrn thre basaloid cells and also positive
within man c[ rhe spindle cells, highlighting up to
L}o/oof the entrre lesion. Thus, the overall histologic
and immunohistochemical findings supported the
diagnosis of pilomalncal carcinoma.
COMMENT
Pilomatrixoma first -asdescribed in 1BB0 by Malherbe
and Chenantaisr as a calci.it'tngepithelioma that was
thought to originate from the sebaceous gland. In
L949, Lever and Griesemerr suggested that the actual
origin of the tumor was the harr matrix.3 Thus, the
approprlaLe term pilomatrtxonta was adopted, synony-
mous with calcifying epithehoma of Malherbe, which
also is commonly used.
Clinically, the tumor is described as a solitary, slow
growing, asymptomatic, dermai or subcutaneous mass
that mosl commonly is found in the posterior neck,
upper back, and preauricular area.Duration of tumors
prior to surgery has been reported to range from
4 months to 10 years.3 Pilomatrical carcinomas have
been reported to range in size from 0.5 cm to 20 cffi,
with a mean of 3.95 cm, which is slightly larger than its
benign counterpart, pilomatrixoma.a The consistency
www.cosderm.com
Figure 1. A 56-year-oldwhite man with a
2-cm, well-demarcated,nontender, move-
able,hard subcutaneousnodule presenton
the right mandiblewith no skinchanges.
of the tumors may vary from soft and friable to firm.
They may have red, yellow, white, and tan skin
changes. Lesions cannot reliably be distinguished
based solely on clinical appearance, and frequently
are mistaken for epidermal cysts. The diagnosis of
pilomatrical malignancyis made exclusivelyby careful
histologicevaluation.
Pilomatricalcarcinomahasa potentialto metastasrze
in about 10o/oof cases.5Casesof metastasisto the lung,
bones, and lymphatics, ds well as invasion into the
cranialvault, havebeenreported.3
EPIDEMIOLOGY
The epidemiology of pilomatrical carcinoma differs
from pilomatrixomas. Pilomatrixomas more often are
seen in women (female to male ratio of 3: I ) and
tend to occur in patients younger than 20 years. The
mean age of patients diagnosed with pilomatrixoma is
B.7 years, rangirg from B months to 19 years.5
Pilomatrixomas occur most commonly on the head,
followed by the upper extremities, neck, trunk, and
lower extremities.3 Involvement of the face has been
reported in the frontal, temporal, cheek, periorbital,
and preauricular regions.6Pilomatrical carcinomas are
more predominant in men and more often middle-
aged or elderly adults. The mean age of patients with
pilomat.rical carcinoma is 48 years, ranging from 2 to
BB years, and in this population are more common
in the posterior neck, upper back, and preauricu-
lar area.3'4Approximately 60o/o of tumors have been
located on the head, among which half are in the
preauricular region.T
vol. 23 No. 7 . JULv2010. Cosmetic Dermatology@ 315
3. PnouATRIcnr CaRcINoMA
Figure 2. A fragrnentedbiopsy specimenrevealed
basaloidproliferationand ghost cells(H&E,original
magnificationx 100).
Figure3. Infiltrativesquamoid and spindle cells
with atypical features, including large nuclei
with prominent nucleoli (H&E,original magnifica-
tion x400).
HISTOPATHOLOGY
The histologic differential diagnosis of pilomatrical
carcinoma includes pilomatrixoma, squamous cell
carcinoffi?, trichoepithelioma, ly-phoepitheliomalike
316 CosmeticDermatology@. JULY2010. vot-.23No.7
carcinoma of the skin, and mixed tumors of the skin.7
Pilomatrical carcinomas have the characteristic features
of epithelial islands of pleomorphic basaloid cells with
vesicular nuclei and prominent nucleoli. Shadow or
www.cosderm.com
4. l
ghostcells,alongwith zonesof necrosiswith surround-
ing stromaldesmoplasiaalsoareobserved.The basaloid
cellshavedeeplybasophilicoval or round nuclei and are
found at the periphery of the islands.A transition zorae
www.cosderm.com
PnouATRrcAL CARCTNoMA
Figure4. Stromalsclerosis,highly atypicalsqua-
moidand spindlecells,and severalmitoticfigures
(H&E,originalmagnificationX400).
Figure5. Areasof hemorrhageandgranulationtis-
suesurroundedby infiltrativeatypicalspindlecells
(H&E,originalmagnificationX400).
of retainednuclei from basaloidcells to the anucleate,
eosinophilicshadowcellsoften is seen.8Tumor necrosis
usually is present, as well as frequent atypical mitotic
figures.Basaloidcellsmayinfiltrate the entiredermisand
VOL.23 NO. 7 . JULY2010. Cosmetic Dermatology@ 317
5. PrlouATRrcAL CnncrNoMA
extendinto the subcutaneousfat, deepfascia,and skel-
etal.muscle.In pilomatricalcarcinoma,the shadowcells
tend to form a nestedpattern, insteadof the flat sheet-
like patternusuallyobservedin benignpilomatrixomas.3
Histologic criteria for pilomatrical carcinoma include
vesselinvasion,mitotic index, apoptoticcount,aswell as
molecularmarkersof cell deathand adhesion.e
IMMUNOHISTOCHEMISTRY
Immunohistochemical studies have not d.finirively
distinguished the markers that differentiate piloma-
trixomas from pilomatrical carcinomas . Lazar et alI0
studied a series of 15 pilomatrical carcinomas and
13 benign pilomatrixomas to assess expression of
B,-catenin using immunohistochemical staining and
DNA sequencing of exon 3 from the Bl-catenin gene,
CTNNBI, the defect that leads to the expression of
pilomatrixomas. B-Catenin is a downstream effector in
the Wnt signaling pathway that signals for proliferarion
and differentiation. Mutations in the CTNNBI gene
encoding B-catenin are present in both benign and
malignant neoplasms. A11cases showed nuclear local-
tzatton of B-catenin, mutations on exon 3, as well as
expression of nuclear cyclin D 1. Howev er, 2 pilomatri-
caI carcinomas exhibited accumulation of p53, which
was absent in aIL 13 benign pilomatrixomas. I0 Past
studies also have reported high constant expression of
CD44v6 and P-cadherin. 11
TREATMENT
The most widely reported treatment for pilomatrical
carcinoma is wide local excision with histologically
confirmed clear margins. Becausepilomatrtcal carcinoma
is identifiable by hematoxylin and eosin srain, Mohs
micrographic surgery also is an excellent treatment
option. Currently, there is no consensus on surgical man-
agement, and standard excisional margins have not been
defined.s Adjuvant radiation therapy may be necessary
postexcision. Chemotherapy has been used in cases of
extensive tumor invasion and in casesof metastasis.
Appropriate Iaboratory testing includes liver func-
tion tests, calcium levels, and chest x-ray examination.
If aggressivelocal invasion is suspected, a computed
tomography scan or magnetic resonance imaging
should be performed to define tumor extension.T Past
studies have found that the radiologic findings of pilo-
matrixoma typically demonstrate a well-circumscribed
lesion with homogeneous or sandlike calcifications on
plain radiograph and computed tomography studies.12
Niwa et aIa reported a case of pilomatrical carcinoma
of the axilla, which demonstrated a diffuse inhomoge-
neous mass with cystic changes on magnetic resonance
rmaging. Areas of low signal intensity corresponded to
318 CosmeticDermatology@. JULv2010. vol. 23No.Z
calcifications, while the inhomogeneous signal intensi-
ties related to varying degrees of tumor proliferation.
High signal intensity was atrributable ro cysric spaces
forming in areasof tumor necrosis
Pilomatrical carcinoma is a rare malignant form
of pilomatrixoma, which arises from hair matrix
cells. Careful histologic evaluation is necessary to
distinguish benign pilomarrixoma from pilomarri-
cal carcinoma. Pilomatrical carcinoma rnay arise
de novo or from a preexisting benign pilomatrixoma,
which may be clinically indistinguishable. In cases
where previously excised or curetted pilomatrixomas
recur, a reexcision with careful histologic evaluation
is indi cated.T
Pilomatrical carcinoma occurs more often in middle-
aged to older individuals, more commonly in men,
and has a predilection for the posterior neck, upper
back, and preauricular area. Pilomatrical carcinomas
frequently recur; however, treatment with wide local
excision or Mohs micrographic surgery has been
shown to lower the raLeof recurrence.4,5
Distant metastaseshave been reported in up to l0o/o
of cases.5Due to the potential for metastasis, prompt
diagnosis followed by wide local excision or Mohs
micrographic surgerl- and close clinical and radiologic
follow-up is recommended.
REFERENCES
1. Malherbe A, ChenantaisJ. ore sur lepirheliome calcifie des
glandessebaces.ProgJIed LSS0:325-837.
2. Lever Wf; Griesemer RD. Calficnng epithelioma of Malherbe;
report of 15 cases,riith ccT-nrnenison its differentiationfrom cal-
cified epidermal cyst anC on iis histogenesis.Arch Derm Syphilol.
L949;59:506-518.
3. sau B Lupton GB Graham JH. Pilomatrix carcinoma. cancer.
L993:7L:249L-2498.
4. Niwa T, YoshidaT. Doiuchi T, et al. Pilomatrix carcinomaof the
axtlla CT and MRI features.BrJ Radiol.20a5;78:257-260.
5. ScheinfeldN. Pilomatricalcarcinoma:a casein a patient with HIV
and hepatitisC. DermatolOnlineJ. 2008;L4:4.
6. YenchaMW Head and neck pilomatricoma in the pediatric age
group: a retrospectivestudy and literature review. Int J Pediatr
Otorhinolaryngol.200I ;57'.123-L28.
7. BarbosaA, Guimaraes N, Sadigursky M. Pilomatrix carcinoma
(malignant pilomatricoma): a casereport and revlew of literature.
AnatsBrasileiros deDermatologia. 2000;75:5BI -5B5.
B. SassmannshausenJ, Chaffins M. Pilomatrix carcinoma:a repori
of a casearising from a previously excised pilomatrixoma and a
review of the literature.J Am Acad Dermatol.2001;44(suppl2).
358-36r.
9. omidi AA, Bagheri R, Tavassollan H. Pilomatrix carcinoma
with subsequentpulmonary metastases:a casereport. Tanaffos.
20065:57-60.
10. Lazar AJ, Calonje E, GraysonW Pilomatrix carcinomascontain
mutations in CTlNBl, the gene encoding beta-catenin.J Cutan
Pathol.2005;32:I 48-L57.
I l. BassarovaA,,NeslandJM, SedloevT, et al. Pilomatrix carcinoma
with lymph node metastes.J CutanPathol.2004;3I:330-335.
12. De BeuckeleerLH, De SchepperAM, NeetensI. Magnetic reso-
nanceimaging of pilomatricoma. Eur Radiol.1996;6.72-60, I
www.cosderm.com